08:07 AM EDT, 08/28/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Wednesday a phase 2 dose-finding study of its investigational drug NBI-1117568 in adult patients with schizophrenia showed 'statistically significant' reduction in symptom severity.

The tests also demonstrated 'statistically significant improvement' in additional scales for schizophrenia symptoms, Neurocrine said. The test's goal was to determine a once-daily well-tolerated dosing regimen, and the results were from a 20 milligrams dose. NBI-1117568 was generally safe and well tolerated at all doses across the study, the company said.

Shares of the company were down nearly 16% in recent Wednesday premarket activity.

Price: 128.35, Change: -24.20, Percent Change: -15.86